Details for New Drug Application (NDA): 022204

✉ Email this page to a colleague

NDA 022204 describes GELNIQUE, which is a drug marketed by Abbvie and Allergan and is included in two NDAs. It is available from one supplier. There are three patents protecting this drug and one Paragraph IV challenge. Additional details are available on the GELNIQUE profile page.

The generic ingredient in GELNIQUE is oxybutynin. There are sixteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the oxybutynin profile page.

Summary for 022204

Tradename:	GELNIQUE
Applicant:	Abbvie
Ingredient:	oxybutynin chloride
Patents:	3

Pharmacology for NDA: 022204

Mechanism of Action	Cholinergic Muscarinic Antagonists

Suppliers and Packaging for NDA: 022204

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
GELNIQUE	oxybutynin chloride	GEL;TRANSDERMAL	022204	NDA	Allergan, Inc.	0023-5861	0023-5861-11	30 PACKET in 1 CARTON (0023-5861-11) / 1 g in 1 PACKET (0023-5861-10)

Profile for product number 001

Active Rx/OTC/Discontinued:	DISCN	Dosage:	GEL;TRANSDERMAL			Strength	10% (100MG/PACKET) Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons
Approval Date:	Jan 27, 2009	TE:		RLD:	Yes
Patent:	10,449,173	Patent Expiration:	Nov 6, 2029	Product Flag?	Y	Substance Flag?		Delist Request?
Patented Use:	TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY, OR URGE INCONTINENCE WITH A SINGLE UNIT DOSE OF 10% OXYBUTYNIN CHLORIDE GEL
Patent:	8,920,392	Patent Expiration:	Mar 26, 2031	Product Flag?		Substance Flag?		Delist Request?
Patented Use:	TREATMENT OF OVERACTIVE BLADDER BY APPLICATION OF OXYBUTYNIN CHLORIDE GEL TO SKIN
Patent:	9,259,388	Patent Expiration:	Nov 6, 2029	Product Flag?		Substance Flag?		Delist Request?
Patented Use:	TREATMENT OF OVERACTIVE BLADDER BY APPLICATION OF OXYBUTYNIN CHLORIDE GEL TO SKIN

Expired US Patents for NDA 022204

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie	GELNIQUE	oxybutynin chloride	GEL;TRANSDERMAL	022204-001	Jan 27, 2009	10,272,061	⤷ Subscribe
Abbvie	GELNIQUE	oxybutynin chloride	GEL;TRANSDERMAL	022204-001	Jan 27, 2009	8,241,662	⤷ Subscribe
Abbvie	GELNIQUE	oxybutynin chloride	GEL;TRANSDERMAL	022204-001	Jan 27, 2009	7,179,483	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.